Navigation Links
Valeant Completes Acquisition of Medicis and Announces Date of 2013 Financial Guidance Conference Call
Date:12/11/2012

MONTREAL, Dec. 11, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced the completion of its acquisition of Medicis Pharmaceutical Corporation ("Medicis") following the approval of the transaction by stockholders of Medicis at the special meeting held on December 7, 2012. Valeant acquired all of the common stock of Medicis outstanding at the time of the completion of the acquisition, for $44.00 per share in cash.

In addition, Valeant will be hosting a conference call and a live Internet webcast along with a slide presentation on Friday, January 4, 2013 at 8:00 a.m. EST (5:00 a.m. PST) to announce 2013 financial guidance.

The dial-in number to participate on this call is (877) 295-5743, confirmation code 80343257.  International callers should dial (973) 200-3961, confirmation code 80343257. A replay will be available approximately two hours following the conclusion of the conference call to Friday, January 11, 2013, and can be accessed by dialing (855) 859-2056 or (404) 537-3406, confirmation code 80343257.

The webcast and slide presentation will be hosted in the investor relations section of its corporate Web site at www.valeant.com. Participants should allow approximately five to 10 minutes prior to the call's start time to visit the site and to download any streaming media software needed to listen to the Internet webcast. An online archive of the webcast will be available following the end of the live call in the webcast archive portion of the investor relations

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Valeant Pharmaceuticals To Host Investor Day
4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
7. Valeant Pharmaceuticals Announces Management Change
8. Valeant Pharmaceuticals To Syndicate Incremental Loans
9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... N.C. , July 24, 2014 ... has signed an Agreement with Kineticos, a ... consulting company. Kineticos will support LSI Medience in ... sepsis management, to demonstrate utility in clinical trials. ... shown potential utility in diagnosis of sepsis, prognosis ...
(Date:7/24/2014)... CAMPBELL, Calif. , July 24, 2014 /PRNewswire/ ... the development of novel interventional devices to facilitate ... United States Patent and Trademark Office has issued ... core technology behind the company,s Lazarus Cover TM ... The Lazarus ReCover is a single-component stent-retriever ...
(Date:7/24/2014)... "North America Orthopedic Braces and Supports Market Outlook to ... Orthopedic Braces and Supports market. The report provides value, ... and average price data (in US dollars), within market ... , Ankle Braces and Supports , Spinal Braces ... Photo - http://photos.prnewswire.com/prnh/20140723/129806 ...
Breaking Medicine Technology:LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2Lazarus Effect Receives Notice of Allowance for New US Patent Covering Core Protection Technology 2North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 2North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 3North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 4North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 5
(Date:7/24/2014)... 2014 The federal judge overseeing ... in the U.S. District Court, District of Massachusetts, ... medical information covered by the federal Health Insurance ... 16th Order, U.S. District Judge Douglas P. Woodlock ... Care the right to receive HIPAA- protected information. ...
(Date:7/24/2014)... Society of Association Executives (ASAE) announced its 2014 Power ... the American Society of Anesthesiologists (ASA). , The ... of A Gold Award, one of the top honors ... betterment of the world through education on the global ... anesthesia care. , ASA was also honored with a ...
(Date:7/24/2014)... Pools and beaches are the place to be on ... for small children, so Amica Insurance is sharing ... Centers for Disease Control and Prevention, children between the ages ... injuries and deaths. It’s important to know the best practices ... offering the following tips from the American Red Cross:, ...
(Date:7/24/2014)... News Facts , Lexmark’s Perceptive ... for compliance with Department of Defense (DoD) security ... Information Assurance Certification and Accreditation Process (DIACAP). The ... DoD as the Enterprise Clinical Imaging Archive, has ... U.S. Army Medical Materiel Agency. , DIACAP certification ...
(Date:7/24/2014)... A new study led by the Translational Genomics Research ... viruses and the immune system during HIV infection. , ... to infect others based on their blood viral ... in their semen despite having low levels in their ... the virus can be found in different parts of ...
Breaking Medicine News(10 mins):Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 4Health News:Keep Kids Safe in the Water with 5 Tips from Amica 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 3Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 4Health News:TGen-led study seeks to understand why some HIV-positive men are more infectious 2
... 10 Enstar Group,Limited ("Enstar") (Nasdaq: ... Enstar Australia Holdings Pty Limited, had entered ... AMP Limited ("AMP") of AMP,s,Australian-based closed reinsurance ... of AUS$585 million (approximately US$518 million)., ...
... it may cause the effect through cerebrovascular disease , ... may be associated with increased risk for mild cognitive ... University Medical Center in New York City. , Mild ... "attracted increasing interest during the past years, particularly as ...
... People rate their smiles higher than dentists do, according ... most important features of an attractive face, the study also ... with their smiles., The study, published in this months Journal ... Norway to rate their own smiles on a 100-point satisfaction ...
... Scheduled for 4:00 p.m. Eastern Time to Review Clinical, Trial ... ... the ASH Meeting, ATLANTA, Dec. 10 ... developing,novel anticancer therapeutics, presented positive results for SNS-595 in,relapsed or refractory ...
... of MGCD0103 Determined as 90 mg, * 53% of Patients ... Responses Experienced a 66% Reduction in the Risk of Death ... Compared to Non-responders, ... (TSX: MYG) today announced maturing data,from the Phase 1/2 study investigating the ...
... 10 Winners of the 2007,Award for Excellence in Human ... and Founder of the Health Improvement,Institute., Winners were: ... Online Clinical Trials Principal Investigator Self ... to educate the University,s researchers on the mechanisms by ...
Cached Medicine News:Health News:Enstar Group Limited Announces Acquisition 2Health News:Hypertension Linked to Risk of Mild Cognitive Impairment 2Health News:Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology 2Health News:Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology 3Health News:Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology 4Health News:Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology 5Health News:Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology 6Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 2Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 3Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 4Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 5Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 6Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 7Health News:2007 Human Research Protection Award Recipients Announced 2
The AutoSet Respond offers ResMeds unique AutoSet algorithm and product quality in a convenient, affordable model. The AutoSet algorithm responds to the patients pressure needs on a breath-by-breath ...
... The AutoSet Spirit is the premium ... flow generators, S7. The AutoSet algorithm responds ... breath-by-breath basis. The flow generator stores and ... software. The AutoSet devices combine integrated ...
These products are primarily for use with paediatric patients and for patients with difficult veins....
... Blood Collection Sets allow you to ... safety. The BD Vacutainer® Safety-Lok™ Blood ... be shielded with one-handed activation. This ... and infusion procedures. It comes with ...
Medicine Products: